Company intelligence / Profile preview

GENIEISO

Ownership: Private
Development stage: Commercial

Overview

Genie Biotech specializes in advanced bioconjugation solutions to accelerate research and development of vaccines, diagnostics, antibody-drug conjugates, nanoparticles, and sustained delivery systems. The company offers site-specific chemistries for assembling various types of drug/protein/antibody conjugates as well as recombinant protein production from its BSL-2 facility. It supports clients from early R&D through transition to commercial product but does not appear to have its own clinical pipeline.

Modalities: Antibody-drug conjugateAntibody fragment-drug conjugateAntibody-oligonucleotide conjugateBispecific monoclonal antibodyNanoparticlePeptide-drug conjugateRecombinant protein
Industry: Drug Discovery Services

Beyond the preview

Go deeper on GENIEISO.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GENIEISO.

Explore the full profile